Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. - Test2 - elhamkhani - TriplyDB

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

http://www.wikidata.org/entity/Q33561644

about

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Gene Therapy 2017: Progress and Future Directions.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Gene therapy research in Asia.Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.IL13RA2 targeted alpha particle therapy against glioblastomas.Adoptive T-Cell Therapy for Solid Tumors.Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.The Microenvironmental Landscape of Brain Tumors.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.Surgical Considerations in the Optimal Management of Patients with Malignant Brain Tumors.Biomarkers and therapeutic advances in glioblastoma multiforme.Therapeutic T cell engineering.HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.Novel Molecular Multilevel Targeted Antitumor Agents Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker.Clinical trials of CAR-T cells in China Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma.Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma.Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Geographic Variations in the Incidence of Glioblastoma and Prognostic Factors Predictive of Overall Survival in US Adults from 2004-2013.Immunotherapy for Pediatric Brain Tumors.Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells.Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.The biology and therapeutic management of melanoma brain metastases.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

P2860

Q33795137-CD6DCB6D-E42D-4142-9A52-F7676F0F132A Q33891559-41EDEA2C-A788-4DBC-84A3-E1F0ABBBD76C Q37728639-7E28B12E-A862-4062-8093-0382F7BCF0CF Q38438763-99E53269-7293-4F50-803E-C1128680FBA5 Q38643300-9957B44F-570B-4022-A3D3-071AF135D2D9 Q38654544-FC2AFB5D-1063-4328-9D04-D758C43D3316 Q38656009-0E8F1248-25FC-4B95-9AFE-D5044AFF9B2F Q38691992-9567E83D-9630-48F8-8802-1EC998201229 Q38754116-E8AB6E7F-62AA-4A29-B0C7-B15B957DA577 Q38754498-EEA0E6D9-374D-4BB2-B297-A68D0C8E1D8E Q38861769-7CB21B5C-A340-41DB-81EA-BEE13264BBF3 Q39178065-FF68D053-A027-44CC-BFD9-446B3D70A033 Q39194733-4F0361D6-F689-4B8A-92B2-5CD0D0D2054E Q39246685-132565C8-7BCF-4B70-A99B-C8D649B72185 Q39253341-D187B66A-7AC0-4AFB-B034-64F13C5D1841 Q39256918-50DA3329-A6B4-4106-9E6A-88595F323BD4 Q39280002-B81024DC-48A6-4358-BF11-C3448778C0B2 Q39294814-D57189A9-9619-4F73-967F-1164EAF2E753 Q39413648-193627F6-B94B-471C-938D-D8132A9DE60A Q39417263-F3AB7BE3-29D1-4552-897E-754CD48CCF47 Q40070524-29282E86-CD5E-4B34-B65F-F628AC0CAEFA Q40199809-581615F0-0941-4571-9D26-ADF2DD4DC06B Q40234446-30C2216A-6D20-4748-B7B7-78DB56EFA762 Q41429679-1264F735-8536-439E-A1E2-CDE5FF36EB9E Q41612568-D7D94530-21E2-4415-A3F9-F046FE37B179 Q42654456-01E2A393-637F-442D-9375-C476BA78D1F4 Q42696122-BD068FCB-0FAD-4776-946B-3C75A7D685B5 Q45074720-B644FC98-90B9-4663-8741-ECC507579588 Q45325460-80E3CE58-0080-4915-ABF8-3315B7C8AD95 Q45868285-B354A5D5-73C5-4DAF-A2C3-8300913ADB3C Q45871070-50C0303D-10D9-4E94-BB44-715FA73E3373 Q45946525-B31469B1-F977-4957-8C72-DBB65DA8692C Q46142965-EDD65535-4707-4CAE-92CB-27639D3717EF Q46407536-EB67A987-CCBE-420E-B5F8-9C121541E34C Q47105810-607AEFF7-0E7D-4A22-AF8F-09CDE84923CE Q47142436-98F215E7-4685-4E3D-9F65-57F384B4F7E3 Q47192478-6A0C68DB-F455-4CD8-BF07-0D68E1EBD5DC Q47193084-E0ACF49D-82D8-4C88-A53C-0FC20B8B77DC Q47247953-D52F8669-D95F-42EB-9254-BEA3B4641E97 Q47285613-5E7054A4-DED3-458D-914A-BE619BDBDCA1

P2860

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

http://www.wikidata.org/entity/Q33561644

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@ast

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@en

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@nl

type

label

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@ast

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@en

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@nl

prefLabel

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@ast

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@en

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@nl

P1433

Q33561644-D599B359-0A21-4574-8FD1-21B362A3CD28

P1476

Q33561644-03016352-288D-467F-AFFC-49B404EEE9AD

P2093

Q33561644-0566E85D-FB7B-4D2B-83BB-296D15D57B75

Q33561644-26630C26-3321-4642-8172-546079DC9E6B

Q33561644-2ACBB63F-3F19-4DFC-8658-C5B3668F6DE9

Q33561644-314B6852-EBA2-4ECE-91B2-BFFB6F08FD52

Q33561644-36889B57-E1D9-4E79-A9AC-B70F7FDB9B96

Q33561644-3A0EF34C-4909-4F05-8F02-D2B4E50F951B

Q33561644-472D2500-CF90-4A14-B3B4-042E067F7EC4

Q33561644-55BCBAAA-6FA8-4789-A470-BADC0D6F9204

Q33561644-6B7508FE-9362-4D61-AF5C-A2731EA14976

Q33561644-73DA2582-94A0-4062-BE64-07FEA5D60190

P2860

Q33561644-08E5DB32-5414-4DA9-B0B3-89250A39BCF3

Q33561644-19EB7E11-C5F3-42DD-80F5-CBC381F30825

Q33561644-344F156C-518A-46B2-9A71-FCD3815CDE2B

Q33561644-35137256-AA00-4B00-BA2E-849C4A41F63B

Q33561644-36241005-7985-42D8-A7CE-D66870A90FA9

Q33561644-5D06351B-618C-457B-9F25-EC9BDCB342B5

Q33561644-78B03374-5E58-4150-A4AB-263CD23FD804

Q33561644-7D2919FE-FB31-40C9-95A2-28AEB8FAD65F

Q33561644-9E5EA7B5-D93A-408C-BD53-46CBD758CC42

Q33561644-A2B733D1-1C78-4594-9A9E-6C222282D787

P304

Q33561644-C51DB3F8-FF13-4519-8F47-DCA52DB3CC8D

P31

Q33561644-10C27029-E919-4741-9A54-DFC6819E7AE3

P356

Q33561644-CCEAA862-6DBC-4C5C-8FD9-7F096D4A4DBC

P407

Q33561644-6E2745FD-15A4-406F-B6BB-67B383AF5C1A

P433

Q33561644-E3B32F9B-6DDC-4563-86DE-039BE0D9A46F

P478

Q33561644-73E45C3D-828E-4889-92E3-0F3D2CC0216F

P50

Q33561644-1B38672A-C99C-4AC3-92A6-56C9DAB42A5E

Q33561644-983E140D-1F0B-48DF-91EF-BFEDF9975636

P577

Q33561644-5271ADF2-EBA3-40DF-BA2B-79581CA51CA8

P698

Q33561644-49F588AE-A3F5-4F93-8C19-61BCA00D9EAB

P932

Q33561644-8802549A-8DD6-4571-9A5A-01D24A050239

P356

P1433

The New England Journal of Medicine

P1476

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

@en

P2093

Anita Kurien

http://www.w3.org/2001/XMLSchema#string

Araceli Naranjo

http://www.w3.org/2001/XMLSchema#string

Behnam Badie

http://www.w3.org/2001/XMLSchema#string

Darya Alizadeh

http://www.w3.org/2001/XMLSchema#string

Jamie R Wagner

http://www.w3.org/2001/XMLSchema#string

Jennifer Simpson

http://www.w3.org/2001/XMLSchema#string

Julie A Ressler

http://www.w3.org/2001/XMLSchema#string

Julie Kilpatrick

http://www.w3.org/2001/XMLSchema#string

Julie R Ostberg

http://www.w3.org/2001/XMLSchema#string

Lihong Weng

http://www.w3.org/2001/XMLSchema#string

P2860

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Novel immunotherapies in lymphoid malignancies

CAR T cells for solid tumors: armed and ready to go?

Smart CARs engineered for cancer immunotherapy

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

P304

2561-2569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1610497

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Christine E Brown

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28029927

http://www.w3.org/2001/XMLSchema#string

P932

5390684

http://www.w3.org/2001/XMLSchema#string